Alternative Excipients for Protein Stabilization in Protein Therapeutics: Overcoming the Limitations of Polysorbates
- PMID: 36559072
- PMCID: PMC9781097
- DOI: 10.3390/pharmaceutics14122575
Alternative Excipients for Protein Stabilization in Protein Therapeutics: Overcoming the Limitations of Polysorbates
Abstract
Given their safety and efficiency in protecting protein integrity, polysorbates (PSs) have been the most widely used excipients for the stabilization of protein therapeutics for years. In recent decades, however, there have been numerous reports about visible or sub-visible particles in PS-containing biotherapeutic products, which is a major quality concern for parenteral drugs. Alternative excipients that are safe for parenteral administration, efficient in protecting different protein drugs against various stress conditions, effective in protein stabilization in high-concentrated liquid formulations, stable under the storage conditions for the duration of the product's shelf-life, and compatible with other formulation components and the primary packaging are highly sought after. The aim of this paper is to review potential alternative excipients from different families, including surfactants, carbohydrate- and amino acid-based excipients, synthetic amphiphilic polymers, and ionic liquids that enable protein stabilization. For each category, important characteristics such as the ability to stabilize proteins against thermal and mechanical stresses, current knowledge related to the safety profile for parenteral administration, potential interactions with other formulation components, and primary packaging are debated. Based on the provided information and the detailed discussion thereof, this paper may pave the way for the identification or development of efficient excipients for biotherapeutic protein stabilization.
Keywords: excipient; polysorbate alternatives; protein biotherapeutic formulations; protein stabilization; surfactant.
Conflict of interest statement
The authors declare no conflict of interest. The company had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.
Figures





Similar articles
-
Brij-58, a potential injectable protein-stabilizer used in therapeutic protein formulation.Eur J Pharm Biopharm. 2020 Jan;146:73-83. doi: 10.1016/j.ejpb.2019.12.001. Epub 2019 Dec 5. Eur J Pharm Biopharm. 2020. PMID: 31811896
-
Polysorbates versus Hydroxypropyl Beta-Cyclodextrin (HPβCD): Comparative Study on Excipient Stability and Stabilization Benefits on Monoclonal Antibodies.Molecules. 2022 Oct 1;27(19):6497. doi: 10.3390/molecules27196497. Molecules. 2022. PMID: 36235038 Free PMC article.
-
Poloxamer 188 as surfactant in biological formulations - An alternative for polysorbate 20/80?Int J Pharm. 2022 May 25;620:121706. doi: 10.1016/j.ijpharm.2022.121706. Epub 2022 Apr 1. Int J Pharm. 2022. PMID: 35367584 Review.
-
Synthesis, characterization and assessment of suitability of trehalose fatty acid esters as alternatives for polysorbates in protein formulation.Eur J Pharm Biopharm. 2010 Nov;76(3):342-50. doi: 10.1016/j.ejpb.2010.08.012. Epub 2010 Sep 9. Eur J Pharm Biopharm. 2010. PMID: 20816956
-
Polysorbate degradation in biotherapeutic formulations: Identification and discussion of current root causes.Int J Pharm. 2018 Dec 1;552(1-2):422-436. doi: 10.1016/j.ijpharm.2018.10.008. Epub 2018 Oct 6. Int J Pharm. 2018. PMID: 30300706 Review.
Cited by
-
Exploring the effects of excipients on complex coacervation.J Colloid Interface Sci. 2025 Oct;695:137808. doi: 10.1016/j.jcis.2025.137808. Epub 2025 May 5. J Colloid Interface Sci. 2025. PMID: 40359635
-
Regulatory Guidelines for the Analysis of Therapeutic Peptides and Proteins.J Pept Sci. 2025 Mar;31(3):e70001. doi: 10.1002/psc.70001. J Pept Sci. 2025. PMID: 39921384 Free PMC article. Review.
-
Physicochemical Comparison of Kolliphor HS 15, ELP, and Conventional Surfactants for Antibody Stabilization in Biopharmaceutical Formulations.Mol Pharm. 2025 Aug 4;22(8):4890-4908. doi: 10.1021/acs.molpharmaceut.5c00519. Epub 2025 Jun 27. Mol Pharm. 2025. PMID: 40578813 Free PMC article.
-
Optimizing Excipient Properties to Prevent Aggregation in Biopharmaceutical Formulations.J Chem Inf Model. 2024 Jan 8;64(1):265-275. doi: 10.1021/acs.jcim.3c01898. Epub 2023 Dec 19. J Chem Inf Model. 2024. PMID: 38113509 Free PMC article.
-
Investigation on the Combined Effect of Hydroxypropyl Beta-Cyclodextrin (HPβCD) and Polysorbate in Monoclonal Antibody Formulation.Pharmaceuticals (Basel). 2024 Apr 19;17(4):528. doi: 10.3390/ph17040528. Pharmaceuticals (Basel). 2024. PMID: 38675488 Free PMC article.
References
-
- Center for Biologics Evaluation and Research (CBER) What Are “Biologics” Questions and Answers. FDA, Center for Biologics Evaluation and Research; Silver Spring, MA, USA: 2019.
-
- Tous G.I., Wei Z., Feng J., Bilbulian S., Bowen S., Smith J., Strouse R., McGeehan P., Casas-Finet J., Schenerman M.A. Characterization of a Novel Modification to Monoclonal Antibodies: Thioether Cross-Link of Heavy and Light Chains. Anal. Chem. 2005;77:2675–2682. doi: 10.1021/ac0500582. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources